cholangiocarcinoma

By Targets:	Akt (1) Antibiotic (1) Apoptosis (7) Bacterial (1) Calcium Channel (1) Caspase (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) Endogenous Metabolite (1) FGFR (5) Fungal (1) FXR (1) HDAC (2) Isotope-Labeled Compounds (1) MDM-2/p53 (2) p38 MAPK (1) PI3K (1) TAM Receptor (1)
By Research Areas:	Cancer (13) Endocrinology (1) Infection (2) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (2)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109099

Pemigatinib Maximum Cited Publications 13 Publications Verification INCB054828	FGFR	Cancer
Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .

HY-14570

Triphen diol	Apoptosis	Cancer
Triphen diol is a phenol diol derivative, which has excellent anticancer activity against pancreatic cancer and cholangiocarcinoma, and can induce pancreatic cell apoptosis through two mechanisms, caspase-mediated and caspase-independent .

HY-N0819

Raddeanin A 1 Publications Verification	Apoptosis	Cancer
Raddeanin A is a natural triterpenoid saponin component of Anemone raddeana, with anti-cancer activities. Raddeanin A exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway .

HY-113308

Taurolithocholic acid 4 Publications Verification	Calcium Channel Endogenous Metabolite	Others
Taurolithocholic acid is a bile acid that has the activity of increasing cell viability, inducing the S phase of the cell cycle, and promoting DNA synthesis in a concentration-dependent manner in the intrahepatic cholangiocarcinoma cell line RMCCA-1. It can also increase the phosphorylation of EGFR and ERK 1/2 and the expression of cyclin D1 in RMCCA-1 cells, and its induced RMCCA-1 cell growth can be inhibited by specific antagonists and inhibitors.

HY-156632

Resigratinib KIN-3248	FGFR	Cancer
Resigratinib (KIN-3248) is an irreversible and orally active covalent inhibitor of FGFR1-4 that effectively inhibits wild-type and drug-resistant mutations (such as FGFR2 V565F, FGFR3 V555M). Resigratinib covalently binds to the Cys492 site of FGFR, blocks the FGFR signaling pathway, inhibits tumor cell proliferation and induces apoptosis. Resigratinib can be used for the study of FGFR2/3-driven solid tumors (such as cholangiocarcinoma and bladder cancer) .

HY-P99463

Batiraxcept AVB-500; AVB-S6-500	TAM Receptor PI3K Akt p38 MAPK	Cancer
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((K_D <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .

HY-109099R

Pemigatinib (Standard)	FGFR	Cancer
Pemigatinib (Standard) is the analytical standard of Pemigatinib. This product is intended for research and analytical applications. Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .

HY-N15136

Isomorellinol	Apoptosis	Cancer
Isomorellinol is a xanthone with an anticancer potency. Isomorellinol induces apoptosis in cholangiocarcinoma cells. Isomorellinol increases the Bax/Bcl-2 protein expression ratio and decreases survivin protein expression in cholangiocarcinoma cells .

HY-W754878

Pemigatinib-d6 INCB054828-d₆	Isotope-Labeled Compounds FGFR	Cancer
Pemigatinib-d₆ (INCB054828-d₆) is deuterium labeled Pemigatinib. Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .

HY-160929

Linafexor CS-0159	FXR	Metabolic Disease
Linafexor (CS-0159) is an agonist for farnesoid X receptor (FXR) .

HY-W040129

Chromomycin A3 1 Publications Verification	DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis Caspase	Infection Neurological Disease Cancer
Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg ²⁺. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .

HY-W040129R

Chromomycin A3 (Standard)	Bacterial Fungal Apoptosis Antibiotic	Infection Neurological Disease Cancer
Chromomycin A3 (Standard) is the analytical standard of Chromomycin A3 (HY-W040129). This product is intended for research and analytical applications. Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg ²⁺. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .

HY-16138

Ivaltinostat CG-200745	HDAC MDM-2/p53 Apoptosis	Cancer
Ivaltinostat (CG-200745) is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat inhibits deacetylation of histone H3 and tubulin. Ivaltinostat induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat induces apoptosis and has anti-tumour effects .

HY-16138A

Ivaltinostat formic CG-200745 formic	HDAC MDM-2/p53 Apoptosis	Inflammation/Immunology Endocrinology Cancer
Ivaltinostat (CG-200745) formic is an orally active, potent pan-HDAC inhibitor which has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. Ivaltinostat formic inhibits deacetylation of histone H3 and tubulin. Ivaltinostat formic induces the accumulation of p53, promotes p53-dependent transactivation, and enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins. Ivaltinostat formic enhances the sensitivity of Gemcitabine-resistant cells to Gemcitabine (HY-16138) and 5-Fluorouracil (5-FU; HY-90006). Ivaltinostat formic induces apoptosis and has anti-tumour effects .

HY-149486

FGFR1 inhibitor 7	FGFR	Cancer
FGFR1 inhibitor 7 (compound 5) is an inhibitor of FGFR1 Tyrosine Kinase with IC₅₀ value of 0.33 nM. FGFR1 inhibitor 7 shows broad-spectrum cytotoxicity agasinst human cancer cell lines, and inhibits MOLT3 cells with IC₅₀ of 2.1 μM .

Cat. No.	Product Name

HY-K6106

*Human Cholangiocarcinoma* Organoid Kit**
MCE Human Cholangiocarcinoma Organoid Kit contains Cholangiocarcinoma Organoid Basal Medium A, Cholangiocarcinoma Organoid Supplement B (50×), Cholangiocarcinoma Organoid Supplement C (250×). This product can be used to efficiently construct human cholangiocarcinoma organoid.

Cat. No.	Product Name	Target	Research Area

HY-P99463

Batiraxcept AVB-500; AVB-S6-500	TAM Receptor PI3K Akt p38 MAPK	Cancer
Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((K_D <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0819

Raddeanin A 1 Publications Verification	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Cancer	Apoptosis
Raddeanin A is a natural triterpenoid saponin component of Anemone raddeana, with anti-cancer activities. Raddeanin A exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway .

HY-W040129

Chromomycin A3 1 Publications Verification	Microorganisms Source classification	DNA Alkylator/Crosslinker DNA/RNA Synthesis Apoptosis Caspase
Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg ²⁺. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .

HY-N15136

Isomorellinol	Structural Classification Xanthones Guttiferae Source classification Phenols Plants Garcinia hanburyi Hook. f.	Apoptosis
Isomorellinol is a xanthone with an anticancer potency. Isomorellinol induces apoptosis in cholangiocarcinoma cells. Isomorellinol increases the Bax/Bcl-2 protein expression ratio and decreases survivin protein expression in cholangiocarcinoma cells .

HY-W040129R

Chromomycin A3 (Standard)	Microorganisms Source classification	Bacterial Fungal Apoptosis Antibiotic
Chromomycin A3 (Standard) is the analytical standard of Chromomycin A3 (HY-W040129). This product is intended for research and analytical applications. Chromomycin A3 is an inhibitor that selectively binds to GC-rich DNA sequences. Chromomycin A3 targets the DNA minor groove after forming a dimer with Mg ²⁺. Chromomycin A3 inhibits DNA replication and transcription, blocks the binding of Sp1 transcription factor to target gene promoters, downregulates the expression of anti-apoptotic proteins such as FLIP, Mcl-1, and XIAP, and induces S-phase cycle arrest and caspase-dependent apoptosis in tumor cells. Chromomycin A3 can antagonize oxidative stress induced by glutathione depletion and neuronal apoptosis induced by Camptothecin (HY-15660). Chromomycin A3 can be used in basic research on malignant tumors such as cholangiocarcinoma, and is a potential chemosensitizer and GC-rich region probe .

Cat. No.	Product Name	Chemical Structure

HY-W754878

Pemigatinib-d6
Pemigatinib-d₆ (INCB054828-d₆) is deuterium labeled Pemigatinib. Pemigatinib (INCB054828) is an orally active, selective FGFR inhibitor with IC₅₀s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively. Pemigatinib has the potential for cholangiocarcinoma .

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

MCE Kits

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Name
Email *

	Sorry, but the email address you supplied was invalid.

cholangiocarcinoma

Inhibitors & Agonists

MCE Kits

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products